# Reviewer simulation

## Acceptance risk assessment

Risk appears **moderate-to-high** for a journal at the *Diabetes Care* tier. The strongest concerns are the absence of external validation for a clinical-prediction model and the discussion's translational overreach (insurer-coverage recommendation built on a single-center, unvalidated AUC=0.79). Both surface under multiple lenses (statistical, methodological, translational). Enthusiasm drivers are real — clinically important question, restrained tone declared in the project state, sensible variable choice — but the prediction-model methodology and the conclusion's reach will likely be the deciding issues in review.

## Likely major critiques

1. **[Statistical, Methodological]** No internal validation reported. The 5-variable logistic model is reported with AUC=0.79 on the development cohort only. With ~64% remission in n=287 (≈184 events), the events-per-variable ratio is reasonable but not generous; bootstrap optimism-corrected AUC or k-fold cross-validation should be reported. Without it, the AUC is over-optimistic by an unknown margin. Likely fatal at *Diabetes Care* unless addressed.

2. **[Statistical]** No calibration metric reported (calibration plot, Hosmer–Lemeshow, calibration intercept and slope). Discrimination (AUC) alone is insufficient for a clinical-prediction paper at this venue. TRIPOD reporting guideline expects both.

3. **[Translational / clinical]** Discussion overclaims. The recommendation that "insurers should consider covering surgery within 5 years of T2D diagnosis based on these findings" is unwarranted — a single-center, unvalidated retrospective model cannot support a coverage-policy recommendation. The conclusion should be scoped to "warrants external validation; if confirmed, implications for referral timing include…"

4. **[Methodological skeptic]** Selection bias for the 24-month follow-up endpoint is not addressed. Patients lost to follow-up, switched centers, or whose data were incomplete were presumably excluded from the analytic cohort — the manuscript does not say how many or how that exclusion was handled (complete-case analysis? multiple imputation?). Pre-op characteristics of excluded patients matter.

5. **[Domain expert]** Comparison to prior models is thin. The model is compared to "previously published scores [@kim2019]" with no discussion of which features overlap, what the prior model's AUC was on its own cohort, whether the present model represents incremental improvement, or whether it would be expected to replicate the same way. The reader cannot tell whether this is a marginal refinement of an existing predictor or a genuinely novel one.

6. **[Methodological skeptic]** The duration-monotonicity claim ("β-cell reserve declines monotonically with disease duration") is asserted without engagement with the obvious confounder: treatment history. Long-duration patients have typically been treated with progressively more aggressive regimens; whether the duration effect is biological β-cell exhaustion or accumulated treatment-related metabolic effect is not addressed.

## Likely minor critiques

(Numbered independently from majors above; "Suggested revisions"
cross-references use the form "minor #N" for clarity.)

1. **[Domain expert]** TRIPOD checklist is not mentioned in the methods. *Diabetes Care* increasingly expects TRIPOD-AI or TRIPOD adherence for clinical-prediction-model papers; including the checklist as a supplementary file is low-friction and reduces reviewer friction.

2. **[Presentation]** "Compares favorably to previously published scores" is vague hedging — replace with the actual AUC comparison.

3. **[Presentation]** Abstract conclusion ("our model can be used to predict diabetes remission … and should be incorporated into pre-operative counseling") is stronger than the discussion supports; tighten to match the more conservative scoping recommended above.

## Potential fatal concerns

The combination of (a) no internal validation, (b) no calibration metric, and (c) policy-level recommendations built on a single-center development AUC could push a methodologically strict reviewer toward "reject as currently presented" rather than "revise." If items 1, 2, and 3 above are addressed substantively, this risk drops to "major revision" territory.

## Enthusiasm drivers

- Clinically important question with a clear bedside implication.
- `MANUSCRIPT_STATE.yaml` declares a restrained tone and forbids hype vocabulary ("cure," "very") — the methods text reflects this.
- Variable selection is clinically sensible (pre-op HbA1c, BMI, duration, C-peptide, age are all defensible predictors with biological rationale).
- 24-month outcome window with off-medication HbA1c criterion is methodologically respectable.

## Suggested revisions (concrete and scoped)

1. **Add internal validation.** Bootstrap optimism-corrected AUC (≥1000 resamples) and report alongside the development-cohort AUC. (Addresses major #1.) ~1 supplementary figure + 1 paragraph in Methods.

2. **Add a calibration plot and report calibration intercept and slope.** Add to supplementary materials with a one-paragraph Methods description. (Addresses major #2.)

3. **Rescope discussion conclusions.** Replace the insurer-coverage recommendation with "warrants external validation in an independent cohort; if confirmed, the findings support consideration of earlier referral for surgically eligible patients within 5 years of T2D diagnosis." Tighten the abstract's "should be incorporated into pre-operative counseling" to match. (Addresses major #3 and minor #3.)

4. **Add a paragraph on cohort construction.** Between the current Methods §2.1 and §2.2 (or wherever the analytic cohort is defined), state n screened, n excluded for missing 24-month follow-up data, n excluded for incomplete pre-operative variables, with a brief description of the excluded patients' pre-op characteristics. (Addresses major #4.)

5. **Expand the comparison to prior work.** Add 2–3 sentences explicitly comparing this model's feature set and AUC to the Kim 2019 score, with a brief argument for what the present work adds. (Addresses major #5 and minor #2.)

6. **Address the duration-vs-treatment-history confound.** Add 2–3 sentences in the Discussion acknowledging that duration is correlated with cumulative treatment intensity and that the present design cannot disentangle β-cell decline from treatment-related effects. (Addresses major #6.)

7. **Add a TRIPOD checklist to supplementary materials.** Low effort, large reviewer-perception payoff at this venue. (Addresses minor #1.)

## Lenses applied

- **Methodological skeptic:** surfaced selection-bias concerns (4), the duration-vs-treatment-history confound (6), and reinforced the validation and calibration gaps (1, 2).
- **Domain expert:** surfaced the weak comparison to prior work (5) and the missing TRIPOD framing (7).
- **Translational / clinical:** surfaced the policy-recommendation overreach (3) and the implications of single-center scope for the broader claims.
- **Statistical:** surfaced the missing internal validation (1) and absent calibration metrics (2) as the dominant concerns at this venue.

Convergence across multiple lenses on the validation/calibration/overreach cluster is the strongest signal in this simulation.

## Cross-checked against MANUSCRIPT_STATE

- **Known weaknesses already declared:**
  - "Single-center retrospective design limits generalizability." — acknowledged; the major critiques do not re-raise this as new, but note that the manuscript's conclusion language does not yet reflect the limitation.
  - "No external validation cohort." — acknowledged; the major critiques treat this as a known issue and focus on what *can* be added internally (bootstrap, calibration) and how to scope the discussion accordingly.
- **Core claims tested:**
  - "Shorter diabetes duration and lower pre-operative HbA1c predict remission" — methodological skeptic + statistical lenses.
  - "Five-variable model achieves AUC=0.79" — statistical lens (validation, calibration).
  - "Earlier surgical referral may improve remission rates" — translational / clinical lens (overreach).

## What this simulation did NOT do

- It is not a substitute for actual *Diabetes Care* reviewers. The Liang 2024 *NEJM AI* benchmark for LLM-vs-human comment overlap is ~30%.
- It did not perform statistical recomputation. The reported AUC, p-values, and sample-size implications were taken at face value. For arithmetic-level verification of reported statistics, use a deterministic tool (Statcheck, GRIM).
- It did not re-execute analyses, replicate the model on the cohort, or fact-check cited literature beyond what the manuscript provides.
- It did not assess reviewer affect, tone, or "Reviewer 2"-style unprofessionalism. Critique content only.
